Skip to main content
. Author manuscript; available in PMC: 2024 May 15.
Published in final edited form as: Circulation. 2023 Nov 30;149(1):e1–e156. doi: 10.1161/CIR.0000000000001193

Recommendations for Inpatient Initiation of Antiarrhythmic Agents

Referenced studies that support the recommendations are summarized in the Online Data Supplement.

COR LOE Recommendations
1 A 1. Patients with AF who are initiating, increasing the dose of, or reinitiating dofetilide therapy should be admitted for a minimum of 3 days to a facility that can provide continuous electrocardiographic monitoring, calculations of CrCl, and cardiac resuscitation, given the potential for proarrhythmia.17
2a B-R 2. In patients with AF, it is reasonable to initiate sotalol therapy in a facility that can provide continuous electrocardiographic monitoring, calculations of CrCl, and cardiac resuscitation, given the potential for proarrhythmia and bradycardia.4,810
2a B-NR 3. In patients with AF who are initiating PITP dosing of flecainide and propafenone with concomitant atrioventricular nodal blocking drugs, it is reasonable to receive the first dose in a facility that can provide continuous electrocardiographic monitoring, given the potential for proarrhythmia.913